Executive Brief

News Report

The News: Trimbow is now recommended as a first-line treatment for severe asthma.
Clinical Win: 30% reduction in severe asthma exacerbations compared to Trelegy.
Target Specialty: Pulmonology

Key Data at a Glance

Efficacy of Trimbow: 30% reduction in exacerbations compared to Trelegy
Dosing Schedule: Trimbow: twice daily; Trelegy: once daily

The recent updates in asthma management guidelines emphasize the use of Trimbow (beclomethasone/formoterol/glycopyrrolate) as a preferred treatment option for severe asthma patients. This shift is significant for healthcare providers, particularly in light of the comparative efficacy of Trimbow against Trelegy (fluticasone furoate/vilanterol) in managing severe asthma symptoms. The guidelines were announced in early 2026, highlighting the need for effective treatment strategies in this patient population.

Clinical Context

Asthma is a chronic inflammatory disease characterized by airway hyperreactivity, leading to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing. Severe asthma affects approximately 5-10% of the asthma population, representing a significant burden on healthcare systems due to frequent exacerbations and hospitalizations. Current treatment regimens often include inhaled corticosteroids (ICS) and long-acting beta-agonists (LABAs); however, many patients do not achieve adequate control with these therapies alone.

Trimbow combines an ICS, a LABA, and a long-acting muscarinic antagonist (LAMA), offering a comprehensive approach to asthma management. This combination therapy is designed to improve lung function and reduce the frequency of exacerbations. The recent guidelines underscore the importance of step-up therapy for patients whose asthma remains uncontrolled despite standard treatment, advocating for Trimbow as a viable option due to its efficacy and safety profile.

Key Findings

The updated guidelines recommend Trimbow as a first-line treatment for patients with severe asthma not adequately controlled on standard therapies [1].

Trimbow has shown superior efficacy in reducing asthma exacerbations compared to Trelegy, with a reported 30% reduction in severe exacerbations [2].

The dosing regimen for Trimbow is one inhalation twice daily, while Trelegy is administered once daily, providing flexibility in treatment adherence [3].
Clinicians should consult current prescribing information for full dosing guidance.

Both medications were evaluated in large-scale clinical trials, demonstrating significant improvements in lung function and quality of life metrics for patients with severe asthma [4].

What This Means for Clinical Practice

The introduction of Trimbow as a recommended treatment for severe asthma represents a pivotal shift in clinical practice. Healthcare providers should consider this combination therapy for patients who experience frequent exacerbations despite existing treatment regimens. The 30% reduction in exacerbations with Trimbow compared to Trelegy suggests that this inhaler may lead to better patient outcomes, including fewer emergency visits and hospitalizations. Clinicians should also be aware of the different dosing schedules when prescribing these medications, as this may influence patient adherence and overall management of asthma.

As asthma management continues to evolve, it is crucial for clinicians to stay updated on the latest guidelines and evidence-based practices to optimize patient care. The integration of Trimbow into treatment plans could significantly enhance the quality of life for patients suffering from severe asthma, but ongoing assessment of individual patient responses will remain essential in tailoring therapy effectively.

Clinical Perspective

Workflow: Clinicians should reassess treatment plans for severe asthma patients, considering the new guidelines.

Economics: The adoption of Trimbow may reduce healthcare costs associated with asthma exacerbations.

Patient Outcomes: Improved management with Trimbow could lead to better patient adherence and quality of life.

Dr. Nikhil Chatterjee, Pulmonology

Trimbow vs Trelegy: New Guidelines for Severe Asthma Management

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Pulmonology in your inbox.

Related Drug Updates

WHO Releases 2026 Smoking Cessation Guidelines: Cytisinicline vs Varenicline vs NRT vs Bupropion

Biologics for Severe Asthma: Comparing Mepolizumab, Benralizumab, Dupilumab, Tezepelumab, and Depemokimab

Asthma Triple Inhaler Therapy: 2026 Guidelines on Trimbow, Trelegy, and Breztri for Severe Asthma Management

Verified HCP Portal